Please find attached the file
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories reported FY2026 standalone revenue of Rs 1,68,120 lakhs (up 8% YoY) but net profit fell 35% to Rs 6,606 lakhs. Consolidated revenue was flat at Rs 1,80,569 lakhs while net profit dropped 83% to Rs 2,031 lakhs due to exceptional items and subsidiary changes. The Board recommended a final dividend of Rs 0.20 per share (face value Rs 2). The company approved a second addendum to its Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the appointed date for transferring the Medical Devices Business to April 1, 2026, with a lump-sum consideration of Rs 19,710 lakhs. Dr. Morepen Limited ceased to be a subsidiary in July 2025 when stake was reduced from 80% to 19.94%. Statutory auditors issued unmodified opinions on both standalone and consolidated results.
Profit decline despite revenue growth indicates margin pressure or one-time charges. The business transfer to subsidiary should streamline operations but creates complexity. Dividend offer provides shareholder return amid uncertain profitability trajectory.